AG
NVAX icon

Algert Global’s Novavax NVAX Stock Holding History

Algert Global’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,690
Closed -$107K – 1295
2025
Q1 		$107K Buy
+16,690
New +$138K ﹤0.01% 1128
2024
Q3 		– Sell
-12,701
Closed -$161K – 1452
2024
Q2 		$161K Buy
+12,701
New +$128K 0.01% 1322
2022
Q3 		– Sell
-15,160
Closed -$780K – 1276
2022
Q2 		$780K Buy
+15,160
New +$785K 0.06% 580

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Algert Global's NVAX Position: Q2 2025 in Review

Algert Global sold out of Novavax (NVAX) in Q2 2025, closing a stake of 16,690 shares — an estimated $107K sold.

Algert Global first reported a position in NVAX in Q2 2022 and held it in 3 quarters. The position peaked at $780K in Q2 2022. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

  • Algert Global reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
  • Algert Global sold 16,690 Novavax shares in Q2 2025, an estimated $107K.
  • Algert Global first reported a position in Novavax in Q2 2022 and held it in 3 quarters.
  • Algert Global's Novavax position peaked at $780K in Q2 2022.
  • 250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Algert Global's 13F filing for Q2 2025, filed 14 Aug 2025.